Advertisement
Advertisement
U.S. markets open in 2 hours 42 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Bioasis Technologies Inc. (BIOAF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0037-0.0037 (-50.00%)
At close: 01:07PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.0074
Open0.0037
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0037 - 0.0094
52 Week Range0.0037 - 0.1840
Volume27,289
Avg. Volume37,833
Market Cap294,304
Beta (5Y Monthly)0.47
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateOct 03, 2023 - Oct 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BIOAF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BIOASIS TECHNOLOGIES INC
    MOH: Raising target price to $351.00MOLINA HEALTHCARE INC has an Investment Rating of HOLD; a target price of $351.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Bioasis Provides Corporate Update and Announces Suspension of Operations

    NEW HAVEN, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today provided an up

  • GlobeNewswire

    Bioasis Provides Update on Business Operations

    NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need provides this update

  • GlobeNewswire

    Bioasis Announces AGM Results and Provides Update on Financial Position

    NEW HAVEN, Conn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, is pleased to announ

Advertisement
Advertisement